Fundraising FoxPolaris Partners — 2020 Investments
12 investments dated 2020 · listed companies and verified rows first · show all
Invivyd is a biopharmaceutical company that develops antibody-based product candidates for the prevention and treatment of serious viral infectious diseases, combining viral surveillance and predictive modeling with antibody engineering.
BiotechHealthtechWaltham, US
Tillman U. Gerngross(Executive Officer, Director)Marc Elia(Founder)inLynn Connolly(Executive Officer)inEric Kimble(Executive Officer)inHalley Gilbert(Executive Officer)inRebecca Dabora(Executive Officer)in
Board seatTerry McGuireTerrance G. McGuire· per SEC Form D
Co-investorsBain Capital Life SciencesForesite CapitalGV (Google Ventures)MRL Ventures FundPremji InvestRA Capital+6 more
Ankyra Therapeutics is a biopharmaceutical company developing drugs, with a team that has collectively contributed to bringing seven drugs to global market approval.
BiotechDeep TechHealthtechMedical DevicesAustin, US
Tillman Gerngross(Executive Officer, Director)
Board seatTerrance McGuire· per SEC Form D · $14.5M raise · filed May 2020
Co-investorsGV (Google Ventures)Fidelity InvestmentsMithril Capital ManagementSands Capital VenturesSpring Mountain Capital
Primmune Therapeutics develops PRTX007, an orally administered, systemically active TLR7 agonist that activates interferon-associated innate immune pathways for use in cancer immunotherapy.
BiotechHealthtechCarlsbad, US
James Appleman(SVP, R&D and CSO, Cofounder)Paulo Rangel(Chief Business Officer and Cofounder)inStephen Webber(Vice President, Medicinal Chemistry, and Cofounder)inCharles McDermott(President & CEO, Director)
BoardTodd J Harris(Director)in
Board seatAmir Nashat· per SEC Form D
Co-investorsBioBritBioRock VenturesSamsara BioCapitalBioqube VenturesOberland Capital
Syros Pharmaceuticals is a Massachusetts gene-control biotech developing small molecules that regulate disease gene expression.
BiotechCambridge, US
Nancy Simonian(CEO)Peter Wirth(Director)Mark Alles(Director)Philip Sharp(Director)Richard A. Young(Director)Sue Gail Eckhardt(Director)
Board seatAmir Nashat· per SEC Form D · $121.6M raise · filed Dec 2020
Co-investorsAisling CapitalARCH Venture PartnersQuan CapitalAlexandriaAlly Bridge GroupBain Capital+11 more
Dyno Therapeutics develops artificial intelligence-powered genetic technologies for gene therapy, specifically engineering adeno-associated virus (AAV) capsids to improve gene delivery for treating genetic diseases.
AI & Machine LearningBiotechWatertown, US
Eric Kelsic(Founder)inSam Sinai(Founder)inAdrian Veres(Founder)inGeorge Church(Scientific Cofounder, SAB)inTomas Bjorklund(Scientific Co-founder, SAB)inAlan Crane(Founder)in
Co-investorsAndreessen HorowitzCRV (Charles River Ventures)GENERAL INCEPTIONGV (Google Ventures)Lux CapitalObvious Ventures+2 more
Montis Biosciences develops anti-C1q antibodies that target both the complement and myeloid axes to treat neuroinflammatory, autoimmune, neurodegenerative and ophthalmic diseases, with a lead program in Guillain-Barré syndrome and a second CD93 program in lung squamous cell carcinoma.
BiotechHealthtechLeuven, BE
Federico Grossi(Clinical Advisor & Acting CMO)
Co-investorsDroia VenturesPfizer VenturesVIBPfizer Venture Investments
Preply is a language learning platform that serves corporate employees through its B2B offering Preply Business, enabling companies to provide language education to their workforce.
AI & Machine LearningB2B MarketplacesEdTechHR TechMarketplacesSaaSBrighton, US
Dmytro Voloshyn(Co-founder and CTO)inKyrylo Bigay(Executive Officer, Director)Kirill Bigai(Co-founder and CEO)inSergey Lukyanov(Former Co-Founder)inCharlie Wickers(Executive Officer)inBoris Shakhnovich(Executive Officer)
Co-investorsAcurio VenturesCogito Capital PartnersDigital Future Investments LtdEducapitalEvli Growth PartnersFlashpoint Venture Capital+18 more
Stensul is a no-code marketing creation platform that lets enterprise marketing teams build emails and other content through governed, collaborative workflows with built-in guardrails.
Enterprise SoftwareMarketing TechSaaSNew York, US
Noah Dinkin(Founder)in
Co-investors515 VenturesFirst Round CapitalJavelin Venture PartnersSageview CapitalUS Venture PartnersAlchemist Accelerator+7 more
Astoria, US
Demetrius Michael Karagas(Executive Officer, Director)Steven Gutentag(Founder)inDemetri Karagas(Founder)
BoardRebecca Kaden(Director)in
Co-investorsAlpha PartnersAlumni VenturesComcast VenturesConnetic VenturesCVS Health VenturesEvolution VC Partners+19 more
Vico Therapeutics develops targeted genetic medicines for neurological disorders, with a focus on antisense oligonucleotide therapies designed to address the underlying genetic causes of diseases like Huntington's disease and spinocerebellar ataxias.
AI & Machine LearningBiotechDeep TechHealthtechMedical Devices
Luc Dochez(Chair and Founder)inJosh Mandel-Brehm(Co-Founder)in
Co-investorsDroia VenturesKurma PartnersPureos BioventuresEQT Life SciencesSeroba Life SciencesEurazeo+1 more
Volastra Therapeutics is a drug discovery and development company working on novel cancer therapies.
BiotechHealthtechNew York, US
Samuel Bakhoum(Co-Founder & Chief Scientific Officer)inLewis Cantley(Founder and Chair of Scientific Advisory Committee)Olivier Elemento(Founder and Scientific Advisor)David P. Southwell(Chief Executive Officer)in
BoardRobert Mittendorff(Director)inJill Goldstein(Director)in
Co-investorsDroia VenturesARCH Venture PartnersB Capital GroupB4 CapitalVida VenturesCatalio Capital Management
.jpeg){kind=logo}
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.